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Abstract Background: Black hypertensive patients are more resistant to angiotensin-
converting enzyme (ACE) inhibitor monotherapy than White patients. This
resistance can be overcome with the combination of ACE inhibitors with
diuretics or calcium-channel blockers (CCBs).
Objectives: The objective of this clinical investigation was to evaluate the
antihypertensive effectiveness of monotherapy with the ACE inhibitor be-
nazepril or the CCB amlodipine and their combination in Black and White
hypertensive patients in two separate studies.
Methods: This was a post hoc analysis of data from two separate studies,
pooled because of their similarities, to increase the sample size. Outpatient
Black and White hypertensive patients were selected for these studies. In
study H2303, 201 patients of both sexes and races, whose mean seated dia-
stolic blood pressure (MSDBP) was ‡95mmHg after 4 weeks of single-blind
treatment with benazepril 40mg/day, were randomized into two groups.
Group 1 received benazepril 40mg/day and group 2 received amlodipine/
benazepril 5/40mg/day, which was uptitrated to amlodipine/benazepril
10/40mg/day at week 4 of the study. In study H2304, 812 similar patients,
whose MSDBP was ‡95mmHg after 4 weeks of single-blind treatment with
amlodipine 10mg/day, were randomized into three groups. Group 1 received
amlodipine/benazepril 10/20mg/day, uptitrated to amlodipine/benazepril
10/40mg/day after 2weeks.Group 2 received amlodipine/benazepril 10/20mg/day.
Group 3 received amlodipine 10mg/day. All three groups were followed up for
6 additional weeks.
Results: This report presents the results of post hoc analysis of pooled data
from two separate but similar studies. Combination therapy resulted in greater
lowering of MSDBP and mean seated systolic blood pressure (MSSBP) than
monotherapy with either benazepril or amlodipine (p < 0.001). With respect to
combination therapy, the combination of amlodipine/benazepril 10/20mg/day
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resulted in greater blood pressure (BP) reductions in White patients than in
Black patients (p < 0.004). In contrast, the combination of amlodipine/
benazepril 10/40mg/day resulted in similar BP reductions in both Black and
White hypertensive patients. There were no serious clinical or metabolic side
effects noted, with the exception of pedal edema, which was more common
with amlodipine monotherapy.
Conclusion: This study showed that combination therapy with amlodipine/
benazepril is more effective in BP lowering than monotherapy with the
component drugs. Black hypertensive patients are responsive to the combi-
nation of amlodipine/benazepril; however, they require higher dose combi-
nations for BP reductions similar to those achieved in White hypertensive
patients.
Introduction
Blood pressure (BP) control rates are improv-
ing but are still far from adequate. The latest re-
port stated that BP control has improved consid-
erably from 25% to 50% at present.[1] Although
these control rates may be true for the recommend-
ed BP goals of <140/90mmHg for uncomplicated
hypertension, the control rates for the more ag-
gressive goal of <130/80mmHg for persons with
diabetes mellitus, chronic renal disease, or coro-
nary heart disease (CHD) are lower.[2-5] Most
studies show that in order to reach these goals,
the majority of patients will require two or more
antihypertensive drugs.[6-10] Calcium-channel
blockers (CCBs) and angiotensin-converting en-
zyme (ACE) inhibitors are still recommended for
first-line therapy for hypertension,[2,3] but given
alone, do not produce BP reductions to currently
recommended BP goals, and in most patients
with stage 2 hypertension, a combination of two
drugs from different classes is recommended.[2-4]
The combination of a CCB with an ACE inhibi-
tor is particularly attractive for patients with
diabetes or hyperlipidemia because both drugs
are metabolically neutral. In addition, the com-
bination of an ACE inhibitor with amlodipine, a
dihydropyridine CCB, will increase the latter’s
antihypertensive effect[11-14] and ameliorate the
incidence and magnitude of pedal edema.[11,12]
The currently available fixed-dose combina-
tion of amlodipine/benazepril 5/10 and 10/20
mg/day has been effective in reducing BP, but
more aggressive treatment of hypertension with
higher-dose combinations may be necessary to
bring BP to goal, especially in populations like
Black patients, who are resistant to treatment.[13]
Several clinical trials have shown that the combi-
nation of ACE inhibitors or angiotensin-receptor
blockers (ARBs) with a CCB is synergistic and
provides greater reductions of BP in a variety of
hypertensive populations, and the vasodilatory
edema seen with the dihydropyridine CCBs is
usually decreased with their combination.[11,12,15-18]
In this report, we present the effectiveness and
safety of a high-dose combination of benazepril
with amlodipine in Black andWhite hypertensive
patients compared with high-dose monotherapy
with benazepril hydrochloride 40mg/day or am-
lodipine besylate 10mg/day.
Subjects and Methods
Study H2303 consisted of 291 completed sub-
jects and study H2304 consisted of 763 completed
subjects. All subjects were well matched for age
and sex and other clinical parameters. Both studies
were multi-center and double blinded. The sche-
matic of both studies is depicted in figure 1. All
participating sites had IRB approval and each
subject signed an informed consent form before
participating in the study.
In study H2303, after a 2-week drug washout
period, all patients with a mean sitting diastolic
BP (MSDBP) of ‡95mmHg and <110mmHg
entered a single-blind period of treatment with
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benazepril 40mg/day for 4 weeks. At the end of
this period, those patients whose MSDBP was
‡95mmHg and <110mmHg were equally ran-
domized to combination therapy with benazepril
40mg plus amlodipine 5mg [amlodipine/benazepril
5/40mg] per day for 4 weeks and then were force-
titrated to amlodipine/benazepril 10/40mg/day
for an additional 4 weeks. The other patients con-
tinued on benazepril 40mg/day for 8 weeks.
In study H2304, the same study design was
followed as in H2303, with the exception that the
single-blind monotherapy period for 4 weeks
consisted of amlodipine 10mg/day. At the end
of 4 weeks, those patients whose MSDBP was
‡95mmHg and <110mmHg were equally random-
ized into three groups. Group 1 was randomized
to amlodipine/benazepril 10/20mg/day for 2 weeks
and then force-titrated to amlodipine/benazepril
10/40mg/day for an additional 6 weeks. Group 2
was randomized to amlodipine/benazepril 10/20
mg/day for 8 weeks, and group 3 continued on
amlodipine 10mg/day for 8 weeks. Patients with
severe hypertension (MSDBP ‡115mmHg and
mean seated systolic blood pressure [MSSBP]
‡180mmHg) were excluded from participation in
the studies. Also, females with childbearing poten-
tial were required to practice an effective method of
contraception in order to participate in the studies
and, in addition, patients with serious medical con-
ditions were excluded from participation.
The sitting BP was measured at approximately
24 – 2 hours after the previous dose of study
medication in the office with a mercury sphyg-
momanometer after 5 minutes of sitting, in the
same arm and by the same person, approximately
80% of the time. Three BP readings 2 minutes
apart were taken, and the values were averaged.
The safety of the drugs was assessed by close

































Fig. 1. Schematic designs of (a) study H2303 and (b) study H2304.
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Statistical Analysis
Because of the similarities of patients receiving
amlodipine/benazepril 10/40mg/day, the data from
these patients in both studies were pooled to increase
the sample size. The baseline demographics at the
end of the baseline monotherapies are listed in
table I. This table lists the baseline data by treat-
ment group for both Black andWhite patients. The
efficacy and safety of treatment regimens was per-
formed by intent-to-treat (ITT) analysis. In this
analysis, all patients who took at least one dose
of randomized study medication and had a base-
line and at least one post-randomization efficacy
measurement were included. Changes in BP from
baseline to endpoint were analyzed using two-way
analysis of covariance models, with treatment and
center as factors and baseline measurements as a
covariate. Treatment-by-center interaction was also
investigated. Within-treatment comparisons were
analyzed using one-sample t-tests. All treatment
comparisons were made at a two-sided significance
level of 0.05. The proportion of patients in each
treatment group achieving a successful reduction in
diastolic BPwas compared using a logistic regression
model with treatment and center as co-factors and
the dichotomous response as the dependent variable.
Results
Continued monotherapy with benazepril
40mg/day after randomization to double-blind
therapy reduced MSDBP from baseline by
7.1mmHg in White patients (p < 0.0001) and by
4.77mmHg in Black patients (p < 0.0002), and
reduced MSSBP by 6.00mmHg inWhite patients
(p < 0.0001) and by 1.85mmHg in Black patients
(p-value not significant). The difference in MSDBP
was not significant between Black and White pa-
tients, but the difference in MSSBP was significant
(p< 0.05).
Continued monotherapy with amlodipine
10mg/day decreased MSDBP from baseline by
9.2mmHg in White patients and by 8.9mmHg in
Black patients (p < 0.001), and reduced MSSBP
by 5.8mmHg inWhite patients and by 9.4mmHg
in Black patients (p < 0.001 for both). There was
no difference in the reductions of MSDBP and
MSSBP between the two groups. The combination
treatment of amlodipine/benazepril 10/20mg/day
decreasedMSDBP from baseline by 12.99mmHg
inWhite patients (p< 0.0001) and by 8.80mmHg in
Black patients (p< 0.0001), and decreased MSSBP
by 13.72mmHg in White patients (p < 0.0001)
and by 8.72mmHg in Black patients (p < 0.0001).
This drug combination resulted in significantly
greater BP reductions in White patients than
in Black patients (p < 0.004). The high-dose
amlodipine/benazepril 10/40mg/day combination
resulted in reductions from baseline of MSSBP
and MSDBP by 14.33 and 13.60mmHg, re-
spectively, in White patients (p < 0.0001) and by
14.89 and 12.79mmHg, respectively, in Black
patients (p < 0.0001).











Patients (n [%]) 432 273 271 165
White 272 [63] 169 [62] 168 [62] 99 [60]
Black 108 [25] 71 [26] 73 [27] 46 [28]
Other minorities not included in the analysis 52 [12] 33 [12] 30 [11] 20 [12]
Body mass index (kg/m2)a 32 32 31 32
Blood pressure (mmHg; MMSBP/MSDBP)a
White 146.5/98.8 145.4/98.3 144.3/97.7 147.7/98.7
Black 149.2/99.4 147.5/98.4 145.7/98.8 149.3/99.4
a Excluding data on other minorities not included in the analysis.
MSSBP =mean seated systolic blood pressure; MSDBP =mean seated diastolic blood pressure.
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In contrast with the low-dose amlodipine/
benazepril combination, there was no significant
difference between the groups receiving the high-
dose combination (p < 0.674). The effects of com-
bination therapy on BP are depicted in figure 2.
The percentages of patients who achieved BP
control (BP <140/90mmHg) and the percentages
of responders to treatment (MSDBP <90mmHg
or ‡10mmHg decrease from baseline) are listed
in table II. In the high-dose combination treat-
ment group, the control rate was identical in
Black and White patients (60.7%), whereas in the
low-dose combination treatment group, the con-
trol rate was higher in White patients than in
Black patients (61.2% vs 39.4%; p< 0.0023). With
respect to the responder rate, there was no dif-
ference between Black and White patients for the
high-dose combination (74.8% vs 77%; p< 0.639).
In contrast, for the low-dose combination, the
responder rate was lower in Black patients than
in White patients (50.7% vs 73.5%; p< 0.007)
[table II].
Most patients tolerated the treatment well, and
there were no serious clinical or metabolic side ef-
fects noted, with the exception of pedal edema,
which tended to bemore common in the amlodipine
monotherapy group (9.2%) than in the amlodipine/











































Fig. 2. The reductions in mean seated systolic blood pressure (MSSBP) and mean seated diastolic blood pressure (MSDBP) were sig-
nificantly lower from baseline to endpoint for both White and Black patients treated with either amlodipine/benazepril 10/40mg/day or amlo-
dipine/benazepril 10/20mg/day (p <0.0001). The between-group comparisons showed a significant decrease in MSSBP and MSDBP inWhite
patients compared with Black patients treated with low-dose amlodipine/benazepril 10/20mg/day (p< 0.004); this racial difference was elim-
inated with high-dose amlodipine/benazepril 10/40mg/day (p =0.388). * p< 0.0001 compared with baseline; - p< 0.004 between groups.
BP = blood pressure.











Control rate: blood pressure <140/90mmHg 0.999 0.002
White 270 [60.7] 170 [61.2]
Black 107 [60.7] 71 [39.4]
Responder rate: MSDBP <90mmHg or >10mmHg decrease 0.640 <0.0007
White 270 [77.0] 170 [73.5]
Black 107 [74.8] 71 [50.7]
MSDBP =mean seated diastolic blood pressure.
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amlodipine/benazepril 10/40mg/day group (4.5%),
but the difference did not reach statistical sig-
nificance. In total, 11 patients discontinued the
studies because of pedal edema, two in the
amlodipine/benazepril 10/20mg group, two in the
amlodipine/benazepril 10/40mg group, and seven
in the amlodipine monotherapy 10mg/day group.
Cough was infrequent and occurred in fewer than
5% of the patients taking benazepril alone or in
combination with amlodipine. Also, mild, non-
significant increases in serum potassium, blood
urea nitrogen (BUN), and creatinine levels were
noted in some patients.
Discussion and Conclusion
Uncontrolled hypertension is a major risk fac-
tor for cardiovascular and stroke morbidity and
mortality. In a meta-analysis of one million hyper-
tensive patients, it was demonstrated that there
was a linear relationship between the rise in systolic
and diastolic BP from 115/75mmHg to 185/115
mmHg and the incidence of cardiovascular com-
plications and strokes for all ages.[19] This anal-
ysis also showed that for each 20mmHg increase
in systolic BP and each 10mmHg in diastolic BP,
the risk of cardiovascular diseases and strokes
doubles. Therefore, aggressive treatment of hy-
pertension, with goals of <140/90mmHg for un-
complicated hypertension and <130/80mmHg
for patients with diabetes mellitus, renal disease,
or CHD, is recommended by the Seventh Report
of the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High
Blood Pressure (JNC-7), the European Society of
Hypertension, the European Society of Cardiol-
ogy, and the American Heart Association.[2-4]
Recently, more aggressive goals for BP reduction
to <135/85mmHg have been recommended by the
International Society of Hypertension in Blacks.[13]
However, it is possible that future guidelines might
relax these strict BP control recommendations
because of conflicting evidence regarding their
benefit.[20]
To accomplish these goals, it is often necessary
to use multiple drug therapies.[2-6] ACE inhibitors
and ARBs are drugs with proven cardioprotective,
renoprotective, and cerebroprotective properties.[21]
However, certain populations, like African-
Americans, are resistant to drugs that block the
renin–angiotensin–aldosterone system [RAAS],
like ACE inhibitors and ARBs given as mono-
therapy,[22,23] because these drugs exert their major
antihypertensive effects through the blockade of
RAAS, and Black patients are usually low-renin
and volume-dependent hypertensive subjects.[24]
Several clinical trials have shown that the
combination of ACE inhibitors with CCBs in-
creases their hypotensive potency[11-17,25] because
of a synergistic effect of inhibition of RAAS and
a direct arterial dilatory effect, which is in-
dependent of RAAS inhibition. Most of the pre-
vious publications have used lower-dose ACE
inhibitor–CCB combinations and did not specif-
ically focus on the antihypertensive effects of
these drug combinations on Black hypertensive
patients compared with their White counterparts.
In this report, we present our findings on low-
dose amlodipine/benazepril 10/20mg/day and
high-dose amlodipine/benazepril 10/40mg/day
combination regimens for the treatment of Black
and White hypertensive patients. Our results
showed that the low-dose amlodipine/benazepril
combination resulted in significantly greater BP
reductions and higher BP control and responder
rates in White compared with Black hypertensive
patients. In contrast, the high-dose amlodipine/
benazepril combination eliminated this racial
difference and resulted in similar reductions in BP
control and responder rates. Other investigators
have also reported that Black hypertensive pa-
tients treated with higher doses of ACE inhibitors
show a greater BP response, compared with lower
doses.[22,26-28]
Combinations of CCBs and ACE inhibitors
or ARBs have complimentary mechanisms of ac-
tion that provide augmented efficacy, with reduc-
tions not only in BP but also in cardiovascular
morbidity and mortality.[29] The combination of
amlodipine with perindopril in ASCOT (the Anglo-
Scandinavian Cardiac Outcomes Trial) resulted
in significant reductions in cardiovascular morbid-
ity and mortality in high-risk hypertensive patients
compared with an atenolol–diuretic combination,
for similar reductions in BP.[30] Also, in the AC-
COMPLISH (Avoiding Cardiovascular Events
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through Combination Therapy in Patients Living
with Systolic Hypertension) study,[31] patients
treated with a combination of benazepril with
amlodipine had a lower incidence of cardiovascular
events than patients treated with a combination of
benazepril with hydrochlorothiazide.
A substudy of ASCOT, the CAFE´ (Conduit
Artery Function Evaluation) study, showed that
the reason for the superior performance of the
amlodipine/lisinopril combination was the re-
duction in central aortic and pulse pressure
compared with the atenolol/diuretic regimen.[32]
Central aortic pressure is more important than
brachial pressure for target organ damage, and
the patients who stand to benefit from this drug
combination are older patients with decreased
vascular compliance, diabetic patients, and
patients with CHD and peripheral vascular dis-
ease.[33] Peripheral edema is a common side effect
of monotherapy with a dihydropyridine CCB
because of arteriolar dilation leading to increased
capillary pressure, which increases the arterio-
lar–venous capillary gradient with fluid exuda-
tion and edema. This hemodynamic imbalance is
ameliorated with the addition of ACE inhibitors
or ARBs, which cause both arteriolar and venous
dilation, enabling the venous system to absorb
the excess tissue fluid.[11,12,34,35]
In our studies, the incidence of pedal edema
tended to be higher with amlodipine mono-
therapy (9.2%) and improved with the addition of
high-dose benazepril (4.5%). Overall, the drugs
were well tolerated, and only minor clinical and
metabolic side effects occurred, not necessitating
patient discontinuation from the studies. Only a
few patients were discontinued because of pedal
edema, and most were in the amlodipine mono-
therapy group.
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